PDX-Derived Pancreatic Cancer Organoid Model

It is well known that pancreatic cancer is characterized by rapid progress and a high fatality rate. Its frequent type is pancreatic ductal adenocarcinoma (PDAC) with a dismal prognosis. Major treatment development limitations in the current phase result from the lack of an in vitro model fully representing the patient tumor environment. At Creative Biolabs, we have accumulated a wealth of experience in 3D biology and are skilled at establishing new 3D models including PDX-derived pancreatic cancer organoids to remove obstacles for your project.

Shortcomings of Common PDX Models

In recent years, it has been reported that patient-derived xenografts (PDXs) can mimic primary cancer to a certain extent. However, the in vitro models are particularly constrained in the clinical setting by the time-consuming issue (approximately 40 days). To sum up, they belong to labor-intensive, and technically challenging models. Besides, such models lack the appropriate tumor niche to faithfully simulate a PDAC patient, so display limited translational value.

Advantages of PDX-derived Pancreatic Cancer Organoid Models

PDX-derived organoid models are previously developed from PDXs based on organoid technology. Frappart et al. have successfully generated the PDX-derived PDAC organoid model, and demonstrated its advantages through a series of extensive experiments.

• Precisely capture key characteristics of the primary tumor and recapitulate the morphology, immunohistochemistry, and molecular profiling similar to tumors in vivo.
• Simply predict drug response in vivo and meet the need for timely treatment after diagnosis for most metastatic tumors.
• Model testing needs less time and labor and is an economical and feasible way compared with the existing preclinical standard prediction tool.
• The PDXO system allows the subclonal selection driven by in vitro culture, which is of significance for obtaining accurate drug prediction.

Fig 1. Schematic representation of patient-derived organoids (PDO) development for precision cancer medicine.¹

Applications

In terms of applications, the feasibility and the predictive nature of the PDX-derived organoid (PDXO) create a window for managing personalized therapies. Current pancreatic cancer PDXO models have shown great potential in establishing the disease model to analyze tumor pathophysiology, drug screening and testing, and personalized therapeutic management. They offer a promising tool to conduct pancreatic cancer research, which will boost new drug discovery and benefit advanced pancreatic cancer patients.

Related Services

After many years of continuous development and growth, Creative Biolabs has extended its business to 3D biology and will constantly explore this novel area in the future. We have set up a powerful technical team and possess sufficient expert resources easy to access, which will help us to walk at the forefront of the industry. At present, an ex vivo physiological model network has been built successfully and continuously enriched, which contains a variety of highly customizable 3D organoid products and is appropriate for various tumor research. Like always, we will offer high-quality PDX-derived pancreatic cancer organoid models and related services listed below. Please contact us in time to obtain more information for any support you want.

3D Biology Based Biomarker Discovery

3D Biology Based Drug Discovery and Development

3D Biology Based Toxicity Evaluation

Supporting Assays

Related Sections:

• Patient-Derived Organoid (PDO) Model
• PDX-Derived Organoid (PDXO) Tumor Model